Five things to know:
1. Patients in the study either received the X-BOLT hip fracture fixation device or a gold standard sliding hip screw device. The implant is designed to reduce reoperation rates.
2. X-Bolt Orthopaedics began recruiting patients for the study in June 2016. The company collaborated with 10 centers that were working with the Orthopaedic Trauma Society.
3. Follow-ups to evaluate the patients were conducted at four months and one-year postoperatively.
4. A previous study found zero patients who received the X-BOLT required revision operations while 6 percent of the standard-group patients required reoperations.
5. Results of the current study are expected to be released in June. The company earned FDA clearance in the U.S. for the X-BOLT in the fourth quarter of 2018.
More articles on devices and implants:
Zimmer Biomet hires outside company to ensure easy office transfer: 5 insights
Rutgers uncovers reason for 15% of joint replacement failures: 5 things to know
Flower Orthopedics system reduces phalangeal joint fusion intraoperative time by 33 percent — 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.